Welcome to our dedicated page for Alpha Tau Medical SEC filings (Ticker: DRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alpha Tau Medical Ltd. (NASDAQ: DRTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Alpha Tau files reports such as Form 20-F annual reports and Form 6-K current reports under the Securities Exchange Act of 1934, reflecting its status as a clinical-stage oncology therapeutics company developing the Alpha DaRT alpha-radiation therapy for solid tumors.
Through these filings, investors can review information that Alpha Tau has furnished about its operations, clinical development, and financial position. Recent Form 6-K reports have attached press releases covering topics such as third quarter financial results and corporate updates, receipt of a radioactive material license for the New Hampshire manufacturing facility, and participation in major healthcare conferences. These documents also indicate how certain reports and exhibits are incorporated by reference into Alpha Tau’s registration statements on Form F-3 and Form S-8.
For those analyzing DRTS, the filings are a primary source for details on research and development spending, marketing and general and administrative expenses, net losses, cash and deposits, property and equipment, lease liabilities, warrants, and shareholders’ equity. They also outline risk factors and other considerations referenced in the company’s Form 20-F and related registration statements.
On Stock Titan, users can view Alpha Tau’s SEC submissions as they are made available from EDGAR and use AI-powered summaries to interpret lengthy documents such as financial statements and exhibits. This helps readers quickly understand key points about Alpha Tau’s clinical-stage business model, funding position, and regulatory reporting without manually parsing every line of each filing.
Alpha Tau Medical Ltd. furnished a press release describing updated results from two first-in-human trials of its Alpha DaRT intratumoral alpha-radiation therapy in pancreatic ductal adenocarcinoma. In a pooled analysis, 100% local disease control was achieved in 19 evaluable patients using modified RECIST v1.1 criteria.
Among these patients, 15 (79%) had stable disease and 4 (21%) had partial responses, despite many being heavily pre-treated or ineligible for chemotherapy. Across 26 treated subjects, only 8 device-associated adverse events occurred in 7 patients (27%), almost all resolving within two weeks, indicating a favorable safety profile. The therapy is delivered via an outpatient EUS-guided procedure designed to fit standard gastroenterology workflows.
Alpha Tau Medical Ltd. filed a Form F-3 shelf registration to offer up to $300,000,000 of securities, including ordinary shares, warrants, debt securities, subscription rights and/or units, to be sold from time to time. The base prospectus notes an at-the-market sales agreement permitting up to $100,000,000 of ordinary shares to be sold through H.C. Wainwright & Co.
The prospectus summarizes clinical-stage progress of the company’s Alpha DaRT® localized alpha-radiation therapy, regulatory milestones in Israel, the U.S. Breakthrough Device designations, and recent MHLW approval in Japan with a post-market surveillance requirement. Net proceeds are for general corporate purposes, including R&D and potential commercialization.
Alpha Tau Medical Ltd. is highlighting new pancreatic cancer research based on its Alpha DaRT® radiation therapy. An abstract combining safety and efficacy data from 58 patients across three prospective pancreatic cancer studies in Canada and Israel has been accepted for presentation at the 2026 ASCO Annual Meeting, a major global oncology conference. The pooled analysis covers endoscopic ultrasound-guided intratumoral Alpha DaRT in locally advanced or metastatic pancreatic ductal adenocarcinoma and reflects growing scientific interest in the company’s pancreatic cancer program, alongside ongoing IMPACT and ACAPELLA clinical trials.
Alpha Tau Medical Ltd. reports two key milestones in developing its Alpha DaRT alpha-radiation therapy for pancreatic cancer. In Europe, the company has successfully treated the first patient in its ACAPELLA multicenter trial in France, testing Alpha DaRT combined with capecitabine in up to 40 patients with inoperable locally advanced pancreatic ductal adenocarcinoma who have completed first-line mFOLFIRINOX chemotherapy.
In the U.S., the FDA has approved an Investigational Device Exemption supplement expanding the IMPACT pancreatic cancer pilot study from 30 to 40 patients and adding newly diagnosed patients treated with gemcitabine/nab-paclitaxel alongside Alpha DaRT. Both ACAPELLA and IMPACT focus on safety, feasibility and early efficacy signals, including tumor response, survival outcomes and conversion to surgical resection, as part of Alpha Tau’s broader global clinical strategy in high-need pancreatic cancer settings.
Alpha Tau Medical Ltd. reports two key milestones in developing its Alpha DaRT alpha-radiation therapy for pancreatic cancer. In Europe, the company has successfully treated the first patient in its ACAPELLA multicenter trial in France, testing Alpha DaRT combined with capecitabine in up to 40 patients with inoperable locally advanced pancreatic ductal adenocarcinoma who have completed first-line mFOLFIRINOX chemotherapy.
In the U.S., the FDA has approved an Investigational Device Exemption supplement expanding the IMPACT pancreatic cancer pilot study from 30 to 40 patients and adding newly diagnosed patients treated with gemcitabine/nab-paclitaxel alongside Alpha DaRT. Both ACAPELLA and IMPACT focus on safety, feasibility and early efficacy signals, including tumor response, survival outcomes and conversion to surgical resection, as part of Alpha Tau’s broader global clinical strategy in high-need pancreatic cancer settings.
Alpha Tau Medical Ltd. announced that clinical data from two Jerusalem trials of its Alpha DaRT® alpha-radiation therapy in pancreatic cancer have been accepted for a first-ever oral presentation at Digestive Disease Week (DDW) 2026.
The abstract, led by Principal Investigator Dr. Harold Jacob, will be presented on May 2, 2026 at 10:30am (Central) in the Pancreatic Cancer I: Diagnosis and Treatment session. The work underpins Alpha Tau’s broader clinical development, including its IMPACT pilot study in the U.S. and plans toward a future pivotal study.
Alpha Tau Medical Ltd. director Avruch Michael filed an initial ownership report showing substantial equity exposure to the company. He holds 1,250,941 Ordinary Shares directly and a further 321,020 Ordinary Shares held indirectly through his spouse. He also reports 4,680 Restricted Share Units, which will vest in full on the earlier of one year from March 9, 2026 or the next annual shareholders meeting, subject to continued service. In addition, he holds multiple option grants over Ordinary Shares at exercise prices ranging from $1.10 to $11.50, with expirations extending from 2027 to 2036. Some of these options are already fully vested, while others are scheduled to vest in full on the same future timeline tied to continued service.
Alpha Tau Medical Ltd. director Nadav Kidron filed an initial statement of beneficial ownership, detailing his current equity position in the company. He directly holds 2,986 ordinary shares, along with restricted share units (RSUs) covering 7,767 and 4,680 ordinary shares. The 7,767 RSUs vest in equal monthly installments over three years starting May 12, 2025, subject to continued service, while the 4,680 RSUs vest in full on the earlier of one year from March 9, 2026 or the next annual general meeting. Kidron also holds options over 35,554 ordinary shares at an exercise price of $2.79 expiring in 2035, which vest monthly over three years from May 12, 2025, and options over 15,527 shares at $6.41 expiring in 2036, vesting in full on the earlier of one year from March 9, 2026 or the next annual general meeting.
Alpha Tau Medical Ltd. director and CEO Uzi Sofer has filed an initial statement of holdings. He reports direct ownership of 1,250,941 Ordinary Shares, plus 4,680 Restricted Share Units that will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting, subject to continued service.
Sofer also holds a large portfolio of stock options over Ordinary Shares at exercise prices ranging from $1.10 to $11.50, with expirations between 2027 and 2036. According to the footnotes, some of these options are already fully vested, while others vest either in full on a one-year schedule tied to March 9, 2026 and the next Annual General Meeting, or in equal quarterly installments over four years starting January 1, 2026, all contingent on his continued service.
Alpha Tau Medical Ltd. director Alan Adler filed an initial ownership report showing his equity stake in the company. He directly holds 54,367 Ordinary Shares and 4,680 restricted share units, which will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
Adler also reports multiple option grants to acquire Ordinary Shares, with exercise prices ranging from $2.98 to $11.50 per share and expiration dates between 2028 and 2036. Some of these options are already fully vested, while others vest on the same future schedule tied to the March 9, 2026 date or the next Annual General Meeting.